Bayer Reveals Phase III Study Results: FINEARTS-HF Achieves Key Goal for KERENDIA® (finerenone) in Heart Failure Patients with Mildly Reduced or Normal Ejection Fraction.

Johnson & Johnson has halted the development of their co-created anti-epileptic drug, ADX71149 (JNJ-40411813), with Addex Therapeutics after analyzing Phase 2 clinical data.

Repotrectinib, marketed under the brand name Augtyro, was FDA approved on November 15, 2023.

Innovent and SanegeneBio Announce Initial Dosing of Participant in Early-Stage Trial of IBI3016 (AGT siRNA).

DefenCath was approved by the U.S. Food and Drug Administration on November 15, 2023.

The paper discusses the identification of a novel negative allosteric modulator of the µ-opioid receptor (µOR) through screening with a DNA-encoded small molecule library.

Adzynma was approved by the U.S. Food and Drug Administration on November 9, 2023.

The US FDA extends approval for Jemperli (dostarlimab-gxly) combined with chemotherapy to all adults with advanced or recurrent endometrial cancer. It is the first immunotherapy showing overall survival benefits.

Ixchiq, the world's first chikungunya vaccine, was approved by the U.S. Food and Drug Administration on November 9, 2023.

Danuglipron is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. Pfizer plans to conduct dose-optimization studies in the second half of 2024.

Vamorolone, marketed under the brand name Agamree, was approved by the FDA on October 26, 2023.

Adaptimmune Gains FDA Accelerated Approval for TECELRA® (afamitresgene autoleucel), the First Engineered Cell Therapy for Solid Tumors in the U.S.